• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by BioPlus Acquisition Corp.

    6/14/23 6:08:02 AM ET
    $BIOS
    Blank Checks
    Finance
    Get the next $BIOS alert in real time by email
    425 1 d523098d425.htm 425 425

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report: June 14, 2023

     

     

    BioPlus Acquisition Corp.

    (Exact name of registrant as specified in its charter)

     

     

     

    Cayman Islands   001-41116   98-1583272

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    260 Madison Avenue

    Suite 800

    New York, New York 10016

    (Address of principal executive offices, including zip code)

    Registrant’s telephone number, including area code: (212) 287-4092

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Units, each consisting of one Class A Ordinary Share and one-half of one Redeemable Warrant   BIOSU   The Nasdaq Stock Market LLC
    Class A Ordinary Share, par value $0.0001 per share   BIOS   The Nasdaq Stock Market LLC
    Warrants, each whole warrant exercisable for one Class A Ordinary Share for $11.50 per share   BIOSW   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     


    Item 7.01.

    Regulation FD Disclosure.

    On June 14, 2023, BioPlus Acquisition Corp (“BIOS”) and Avertix Medical, Inc. (f/k/a Angel Medical Systems, Inc.), a Delaware corporation (“Avertix”) will make available a joint investor presentation concerning their previously announced proposed business combination. A copy of the investor presentation is furnished herewith as Exhibit 99.1.

    The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of BIOS under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information contained in this Item 7.01, including Exhibit 99.1.

    Important Information About the Transactions and Where to Find It

    This Current Report on Form 8-K may contain information relating to a proposed business combination between BIOS and Avertix. In connection with the proposed transaction, BIOS has filed a registration statement on Form S-4 (as amended or supplemented, the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”), which includes a preliminary proxy statement/prospectus of BIOS, which will be both the proxy statement to be distributed to holders of BIOS’ ordinary shares in connection with the solicitation of proxies for the vote by BIOS’ shareholders with respect to the proposed business combination and related matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued in the business combination. After the Registration Statement is declared effective, BIOS will mail a definitive proxy statement/prospectus and other relevant documents to its shareholders. BIOS shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus, and amendments thereto, and the definitive proxy statement/prospectus in connection with BIOS’ solicitation of proxies for its shareholders’ meeting to be held to approve the proposed business combination and related matters because the proxy statement/prospectus will contain important information about BIOS and Avertix and the proposed business combination.

    The definitive proxy statement/prospectus will be mailed to shareholders of BIOS as of a record date to be established for voting on the proposed business combination and related matters. Shareholders may obtain copies of the proxy statement/prospectus, when available, without charge, at the SEC’s website at www.sec.gov or by directing a request to: BioPlus Acquisition Corp., 260 Madison Avenue, Suite 800, New York, NY 10026 or by emailing [email protected]

    Participants in the Solicitation

    BIOS and Avertix and their respective directors, officers and other members of their management and employees may be deemed to be participants in the solicitation of proxies from BIOS’ shareholders with respect to the proposed business combination and related matters. Investors and securityholders may obtain more detailed information regarding the names, affiliations and interests of the directors and officers of BIOS and Avertix in the proxy statement/prospectus relating to the proposed business combination filed with the SEC. These documents may be obtained free of charge from the sources indicated above.

    No Offer or Solicitation

    This Current Report on Form 8-K is for informational purposes only and is not intended to and shall not constitute a proxy statement or the solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy or subscribe for any securities or a solicitation of any vote of approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.


    Forward-Looking Statements

    This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are not historical facts, and involve risks and uncertainties that could cause actual results of BIOS and Avertix to differ materially from those expected and projected. These statements, other than statements of present or historical fact included in this document, regarding BIOS’ proposed business combination with Avertix, BIOS’ ability to consummate the proposed transactions, the benefits of the proposed transactions and the combined company’s future financial performance, including financial projections, as well as the combined company’s strategy, demand for products and services, use cases for products and services, anticipated business model and future operations, estimated financial position, estimated revenue growth, prospects expectations, estimated market growth, size and opportunity, plans and objectives of management, among others, are forward-looking statements. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of Avertix’s management and are not predictions of actual performance, and, as a result, are subject to risks and uncertainties. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: the inability of the parties to successfully or timely consummate the proposed business combination; the risk that the proposed business combination may not be completed by BIOS’ business combination deadline and the potential failure to obtain an extension of the business combination deadline by BIOS; failure to realize the anticipated benefits of the proposed business combination; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement; Avertix’s history of operating losses; Avertix’s ability to engage physicians to utilize and prescribe its solution; changes in reimbursement practices; technological changes in Avertix’s market; Avertix’s ability to protect its intellectual property; Avertix‘s material weaknesses in financial reporting; and the Avertix’s ability to navigate complex regulatory requirements. The foregoing list of factors is not exhaustive. Please carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the final prospectus to BIOS’ registration statement on Form S-1, as amended (File No. 333-249676), the Registration Statement filed with the SEC by BIOS and other documents filed or that may be filed by BIOS from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those obtained in the forward-looking statements.

    There may be additional risks that neither BIOS nor Avertix presently know or that BIOS and Avertix currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect BIOS’ and Avertix’s expectations, plans or forecasts of future events and views as of the date of this document. BIOS and Avertix anticipate that subsequent events and developments will cause BIOS’ and Avertix’s assessments to change. However, while BIOS and Avertix may elect to update these forward-looking statements at some point in the future, BIOS and Avertix specifically assume no obligation and do not intend to do so, nor do they intend to revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing BIOS’ and Avertix’s assessments as of any date subsequent to the date of this document. Neither BIOS nor Avertix gives any assurance that either BIOS or Avertix, or the combined company, will achieve its expectations. Accordingly, undue reliance should not be placed upon the forward-looking statements as predictions of future events.


    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

    No.

       Description
    99.1    Investor Presentation, dated June 14, 2023.
    104.1    Cover page interactive data file (embedded within the Inline XBRL document).

     

    *

    Certain exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). BIOS agrees to supplementally furnish a copy of any omitted exhibit or schedule to the SEC upon its request.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    BioPlus Acquisition Corp.
    By:  

    /s/ Ross Haghighat

    Name:   Ross Haghighat
    Title:   Chief Executive Officer and Chief Financial Officer

    Dated: June 14, 2023


    Exhibit 99.1


    ! #$%&’()) * + ,! -( * - +* ++ -.(/ 0 123#)4,4.! 0 5 123#$!&$.(/&’6% *.7*83#$6295&$5%.8&’ #$% 6*8 +&’)*36( -!!%1* - + (!+ !*+ -3 :*/ -)62951%) - +#’*# - ’1#’ 1#’*)* *( *)!#(’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’1! W 5A\+) -5Z8+6295* ) +) +6295) -5Z83) !) ,** ** ( * )) ) ) -A ,! 3 2)), X** (1* * * )) ) * +) -A ,! 3 + ,6295! , -6295!* + ( * ** * ))) ) -A ,! 321) -A ,! ) 6295B!B/1 )))**(( -)) %36295!*+7*(( - *6295B!B !3‘ -(1 - 6295! *) -A ,! )**16295! ) * + !1() -A ,! 1 -* ) -) 1)**(1 -1/ +7*+ + -3) -A ,! * + *!6295B!B )*+7*)%3@6295!!(*6295!1 + 1 - (/3.! 1** * + *) -A ,! ))**(3


    ! !# ! $# %&# ’%# ($ !#!)!*#!)$ (#$+, #-#$! ! $ ’$ #$ !.)!$$ &$$( ’- !$ ’ / ! #(#0 # ’-)!$$ &!0-# 1 !$ # ’ ) !2 #!0 # !& # ’ ! ! !# !+3!0 !-$-#& # ’! # ’ ) !2 ! !# ! $! ! ! !$ &((#-#& # ’!+4567!#2$$( ’! .) 2 ! (- !& # ’ ! ! $-#$! !+8(##9& !! )$ ! !# ! /#-#-#.0#2 ! #! / -# % ’-!035:;3$!#$+#2 $(##!)0 !-# $$ &(-) & !2 $& !! )$ ’-)0 / -(.) ’-!0!7< :#=( #’!$+ >?@ A?B 4567!#2 /! #%# 2$ %# ($# ’#C$9$#% ’#C$!#! ’$0($ ! !! ! / -# ! & ##$- %.($ !$$$+ $-#$! ! ’0)$ ! !# ’#C$9$#% ’#C$9#! ’$! -0# 2$ & #-# $9 / #-# -#0 & ##$- % /!#$+($ # $-)0 & #-# $D# ’#C$9$#% ’#C$9#! ’$ #-# ($ ! $-#$! ! $! !! 9! $! ’-)09#) !$ -/ 4567 ##29 #!! #$’! #$- !$ #$ -.0 # &4567 ##2+7 ))0& # !%! !9# ’#C$9$#% ’#C$9#! ’$! -0# 2$#&## ! $-#$! ! ’0--# / ( E97 E9F #G$0 ’. )$9.($(#&#!$#! !! ! 9 !!0 /094567 ##2 / ))! $$#9 &())$*!(!#--) .))/9 ## 2$ ## 2 &--) .)) !$ # $# ’#C$9$#% ’#C$9#! ’$! -0# 2$+ H?IJKL -# 1 !$9$ ’$!#2$ ! $;#$! !#& # /#M) C !2$ ’!$#.$ !$$( ’- !$# !#!)0$(.1 $ 2! & !(!# ! $! ! !2! $9 ’!0 & / #.0 !4567D!#2D$ !# )+ N )))-# 1 !$9 $ ’$!#2$#!$$# )0$-() %94567!#2.) %-#-# ! &-# $- %& !! ) !& # ’ ! !% )%$ !#$ !2)0 2#)%)$ &(!# !0&(## (-# 1 !9$ ’ ##2*!$&# ’ &-#-# !+ $$( ’- !$!$ ’$(!#)0 !2-# 19*- ##2#$()$# !#!)0(!# !!#$(.1 / %# 0 &$ 2! & !.($ !$$9 ! ’ 9#2() #0! ’- %# $C$!(!# ! $ ()($()#$()$ O# ’# ))0&# ’ $ ! ! !$(-# 1 !$9$ ’$!#2$+ !)($ ! &-# 1 !$9$ ’$!#2$ ! $-#$! !$ ()! .#2#$! ! !4567!#29 # ##-#$! %$9 !$ # # !$ #& !! )-# 1 !$9$ ’$! #2$ .#) .)-# ! &&((#%!$+ PKLLJKQRL? AKL & !! ) !& # ’ !! ! ! ! $;#$! ! $(!( ! $! !& # ’ S2() !7MT+3 # !2)09$( !& # ’ !! ’0! . !)( !9 ’0.1($ ! # ’0.-#$! &&#!)0 !9!0-# *0$ ’! ##2 $# ! $ ’! .& ).04567 ##2 / 7<:+ R AU?LRL?AKL?RLV?L@WJBXQ@? 4567!#2! ##$- % # #$!*( % && #$9(!#7<:#()$9 ’0. ’ .-# -!$ !$ ) ! &-# * $ &4567D$# )#$ ! !! ! / ; ! )4($ !$$: ’. ! !+5!%$ #$!$(# 0 )#$ ’0 . ! ’ # ) !& # ’ !#2# !2! ’$! !#$$ !; ! )4($ !$$: ’. ! ! &4567D # #$! && #$ !4567D& ) !2$ / 7<:9 !)( !24567D#2 $# !$ ’! !8 # ’7MY9 / /$ # 2 !))0& ) / 7<: !Z()0[\9[\[Y+ *! ) !2$ &4567D$(# $%!2&# ’ ’ (!$#- # !4567D#2 $# !$ ’! !8 # ’7MY9$(!2$%.! # / )).#&) !7 ’!$ &:!2 !6 /!#$ - !8 # ’]& ) / 7<:+5!& # ’ !#2# !2-#$ !$ / ’09(!# 7<:#()$9. ’-# -!$ !$ ) ! &-# * $ 4567D$# )#$ ! !! ! / ; ! )4($ !$$: ’. ! ! $$& # !#2 $# !$ ’!& ).04567 !8 # ’7M]^$ ’! #$(--) ’!9_S2 $# !7 ’!‘a9 / !)($-#) ’ !#0-# *0$ ’!b-# $-($ &45679 / / )).. -# *0$ ’! . $# .( )#$ &4567D # !#0$#$ ! !! ! / $ ) ! &-# * $& #% .04567c$# )#$ / #$- -# - $.($ !$$ ’. ! !!#) ’#$$ ’0.$# . !S2 $# !7 ’!9$ /))$-# $-($#) !2 &&#!$) &$(# $ . $$( !;# - $4($ !$$: ’. ! !+3&#S2 $# !7 ’! $)#&& %94567/ )) ’ ) & ! %-# *0$ ’!b-# $-($! ##)%! ( ’!$ $$# )#$+4567$# )#$! # !#$-#$ !$#% $ #9 /!% ).)9-#) ’ !#0-# *0$ ’!b-# $-($9! ’! ’!$# 9!& ! %-# *0 $ ’!b-# $-($ ! !! ! / 4567D$ ) ! &-# * $& # $$# )#$D ’ !2 .) --# %;# - $4($ !$$: ’. ! !!#) ’#$.($-# *0$ ’!b-# $-($ / )) ! ! ’- #! !& # ’ !. (4567!3%# * !;# - $4($ !$$: ’. ! !+ $;#$! ! $! $(.$ (& ##2 $# !$ ’! #& #!0 # ( ’!4567 ’0& )/ 7<: ! !! ! / ; ! )4($ !$$: ’. ! !+5,d<76S73,e7<:fS5gh6ie<S73S<fSj<e6S<3eh<e6:f E<,785i<eN5hh<7<: :3S<8fiig3,e5,h<5S<,5S<g Nh<,h<g4<:6 E<3d35i34i<4<:3f7<h<g N5ii:6,35,5 E;6S3,5,86S E356,+5!%$ #$!$(# 0 )#$ ’0 . !&# - $ & # ( ’!$& ) / 7<:.04567# (2 /.$ ’ ! !.07<: -kbb ///+$+2 %+ 5,d<7E<,5,3,g7<:fS55<7e<7:S54<eh<S<5,h37,64<<,3;;S6d<e6Se573;;S6d<e4gh<7<:6S3,g6h<SS<jfi36Sg3fh6S5g,6Sh373,g3fh6S5g;377<ef;6,6S<,e6S7<eh< E<S5768h<688<S5,j6Sh<3::fS3:g6S3e<lf3:g 68h<5,86S E356,:6,35,<eh<S<5,+3,gS<;S<7<,356,6h<:6,S3Sg573:S5 E5,3i688<,7<+


    ! #$%&’ ()*+,-./01210.2-3,43536+,1-.789322+217: ;1473-1<0.+*+3,2=2-1.76,35.-1>.9.-4.7-0+5=-=,+? @++/6+<--3.7<=,9322+253,-0+53,+2++1>9+5=-=,+A17:3=,1>.9.-4-31<0.+*+17: ;1.7-1.76,35.-1>.9.-4:+6+7:237-0+<3 ;;+,<.192=<<+2235-0+B=1,:.17C42-+ ;? ()*+,-./,+D=.,+21::.-.3719<16.-19-32=663,-.-26,+2+7->=2.7+22691717:17-.<.61-+:>=2.7+228,3 E-0A17:2=<0<16.-19 ;1473->+1*1.91>9+371<<+6-1>9+-+, ;2A3,1-199A E0.<0 E3=9:1:*+,2+94155+<-.-21>.9.-4-336+,1-+? ()*+,-./F2>=2.7+22.2:+6+7:+7-=6376042.<.172=-.9.G.7817:6,+2<,.>.78.-2239=-.37H.5)*+,-./51.92-3+7818+6042.<.172-3=-.9.G+.-2239=-.37A.-2,+*+7=+2 ;147+*+, ;1-+,.19.G+3, ;1473- ;++-.-26,3I+<-.372? J3,+3*+,A.5 E+1,+=71>9+-3+:=<1-+<9.7.<.17237-0+215+A +55+<-.*+17:166,36,.1-+=2+353=,6,3:=<-17::+2.87+:2=,8+,4A E+ ;14+/6+,.+7<+.7<,+12+:<91. ;2356,3:=<-9.1>.9.-417: ;14>+=71>9+-31<0.+*+3=,+/6+<-+:8,3 E-0? ()*+,-./F253,+<12-217:6,3I+<-.3721,+>12+:=637122= ;6-.372A171942+217:+2-. ;1-+2:+*+936+:>4.-2 ;1718+ ;+7-?K5-0+2+122= ;6-.372A171942+23,+2-. ;1-+26,3*+-3>+.7<3,,+<-3,.71<<=,1-+A)*+,-./F21<-=19,+2=9-2 ;14:.55+, ;1-+,.19945,3 ;-032+53,+<12-+:3, 6,3I+<-+:? ()*+,-./F2,+*+7=+,+9.+237-0+B=1,:.17C42-+ ;A E0.<0.2<=,,+7-94.-23794355+,.78?K5-0+B=1,:.17C42-+ ;3,5=-=,+355+,.78251.9- 381.7A3,932+A ;1,L+-1<<+6-17<+A)*+,-./F2>=2.7+22 E.992=55+,? ()*+,-./F22=<<+22:+6+7:237.-21>.9.-4-3+55+<-.*+94 ;1,L+-.-2B=1,:.17C42-+ ;181.72--032+35+/.2-.783,7+ E-+<073938.+2.7-0+ ;1,L+-? (K5)*+,-./.2=71>9+-3L++6=6E.-0:+ ;17:53,-0+B=1,:.17C42-+ ;A.-2,+*+7=+<3=9:>+. ;61.,+:A ;1,L+-1<<+6-17<+53,-0+B=1,:.17C42-+ ;<3=9:>+01, ;+:A17:6042.<.172 ;14.72-+1:3,:+,19-+,71-.*+-,+1- ;+7-2? (K5)*+,-./.273-1>9+-3 ;1.7-1.71:+D=1-+9+*+9235-0.,:M61,-4,+. ;>=,2+ ;+7-53,.-2B=1,:.17C42-+ ;A.- E3=9:01*+1 ;1-+,.191:*+,2++55+<-37.-2>=2.7+22? (N0178+2.7,+. ;>=,2+ ;+7-6,1<-.<+235-0.,:M61,-46143,2<3=9:155+<--0+:+ ;17:53,-0+B=1,:.17C42-+ ;17:)*+,-./F2,+*+7=+9+*+92? (O+. ;>=,2+ ;+7->4 J+:.<1,+.20.8094,+8=91-+:17:2=>I+<--3<0178+H17451.9=,+-3<3 ;694 E.-01669.<1>9+,+8=91-.372<3=9::+<,+12+)*+,-./F2+/6+<-+:,+*+7=+17: ;142=>I+<-.--36+719-.+23,01*+171:*+,2+. ;61<-37.-2>=2.7+22? (K5,+. ;>=,2+;+7-3,3-0+,614 ;+7-53,-0+B=1,:.17C42-+ ;.2,+:=<+:3, ;3:.5.+:.7-0+P7.-+:C-1-+2A.7<9=:.78-0,3=80<32-<37-1.7 ;+7- ;+12=,+23,<0178+2-3639.<.+2 E.-0,+26+<--36,.<.78A)*+,-./F2>=2.7+22<3=9:2=55+,? ()*+,-./.2.7<,+12.7894:+6+7:+7-372360.2-.<1-+:.753, ;1-.37-+<073938417:.5.-51.92-3+55+<-.*+94 ;1.7-1.73,6,3-+<-.-2.753, ;1-.37242-+ ;23,:1-1A.7<9=:.785,3 ;:1-1>,+1<0+2A.-2>=2.7+22<3=9:>+1:*+,2+94155+<-+:? ()*+,-./<3=9:>++/632+:-32.87.5.<17-9.1>.9.-4<91. ;2.5.-.2=71>9+-33>-1.7.72=,17<+1-1<<+6-1>9+<32-217:1:+D=1-+9+*+923,3-0+, E.2+6,3-+<-181.72-63-+7-.196,3:=<-9.1>.9.-4<91. ;2? (K5)*+,-./51.92-3,+-1.7<+,-1.735.-2L+46+,2377+917:1--,1<-17:,+-1.71::.-.3719D=19.5.+:6+,2377+9A.- ;.80-73->+1>9+-36=,2=+.-28,3 E-02-,1-+84? (K7-+,71-.3719+/6172.3735)*+,-./F2>=2.7+22.2+/6+<-+:-39+1:-3.7<,+12+:+/632=,+-3 ;1,L+-A,+8=91-3,4A639.-.<19A36+,1-.3719A5.717<.1917:+<373 ;.<,.2L21223<.1-+:E.-0:3.78>=2.7+223=-2.:+35-0+P7.-+:C-1-+2? (Q0+.7:=2-,4.7 E0.<0)*+,-./36+,1-+2.20.8094<3 ;6+-.-.*+17:2=>I+<--3,16.:-+<073938.<19<0178+?K5<3 ;6+-.-3,21,+>+--+,1>9+-3:+*+93617: ;1,L+-6,3:=<-2-01-1,+215+,A ;3,++55+<-.*+A9+22<32-94A+12.+,-3=2+A3,1,+3-0+, E.2+ ;3,+1--,1<-.*+A E0.<0E3=9:81.7 8,+1-+,1<<+6-17<+.7-0+ ;1,L+-691<+A)*+,-./ ;14>+=71>9+-3<3 ;6+-++55+<-.*+94 E.-03-0+,<3 ;617.+2? (Q0+NRSKTMUV617:+ ;.<3,3-0+,5=-=,+893>190+19-0+ ;+,8+7<.+2 ;14 ;1-+,.199417:1:*+,2+94. ;61<-3=,>=2.7+22A36+,1-.78,+2=9-2A5.717<.19<37:.-.3717:9.D=.:.-4?K5-0+. ;61<-25,3 ;-0+NRSKTMUV617:+ ;.<+/-+7:>+437:3=,122= ;+:-. ;+9.7+23,7+ E893>190+19-0 + ;+,8+7<.+2+ ;+,8+A3=,1<-=19,+2=9-2 ;14*1,42.87.5.<17-945,3 ;3=,+/6+<-1-.372? (P751*3,1>9+893>19+<373 ;.<<37:.-.372A.7<9=:.78293 E+,8,3 E-03,,+<+22.37A.7591-.373,:+<,+12+2.7<372= ;+,26+7:.7863 E+,3,<375.:+7<+A<3=9:1:*+,2+94155+<-3=,>=2.7+22A5.717<.19<37:.-.373,,+2=9-23536+,1-.372? W’X&Y Z [ (K7-+99+<-=196,36+,-49.-.81-.3717:.75,.78+ ;+7-<91. ;2<3=9:<1=2+)*+,-./-3.7<=,2.87.5.<17-+/6+72+23,6,+*+7-.-5,3 ;2+99.78-0+B=1,:.17C42-+ ;17:5=-=,+.-+,1-.372? (K5)*+,-./.2=71>9+-36,3-+<-.-26,36,.+-1,4,.80-2A3,.5.-.75,.78+237-0+6,36,.+-1,4,.80-2353-0+,2A.-2<3 ;6+-.-.*+7+2217:>=2.7+226,326+<-2 ;14>+ ;1-+,.1994:1 ;18+:? (T+6+7:+7<+376,36,.+-1,4,.80-217:51.9.78-36,3-+<-2=<0,.80-23,-3>+2=<<+225=9.79.-.81-.37,+91-+:-32=<0,.80-2 ;14,+2=9-.7614 ;+7-352.87.5.<17- ;37+-1,4:1 ;18+23,. ;61<-)*+,-./F21>.9.-4-32+99.-26,3:=<-2? \’&]X& ’^’_&ZZ[‘a’ \’^b’ (K7-+,,=6-.3735 ;17=51<-=,.7836+,1-.372<3=9:1:*+,2+94155+<-)*+,-./F2>=2.7+22A5.717<.19<37:.-.3717:,+2=9-23536+,1-.372? (T.2,=6-.372.7-0+2=669435-0+ ;1-+,.19217:<3 ;637+7-2=2+:.7 ;17=51<-=,.78)*+,-./F26,3:=<-23,-0+2-+,.9.G1-.3735.-26,3:=<-2>4-0.,:M61,-42=669.+,2<3=9:1:*+,2+94155+<-.-2>=2.7+22A5.717<.19<37:.-.3717:,+2=9-23536+,1-.372? ()*+,-./:+6+7:237-0.,:M61,-4*+7:3,253,-0+2=669417: ;17=51<-=,+35<+,-1.7<3 ;637+7-235-0+B=1,:.17C42-+ ;A12 E+991253,3-0+,126+<-235.-236+,1-.372? ()*+,-./F2:+6+7:+7<+3719. ;.-+:7= ;>+,352=669.+,2-36+,53, ;-12L2=7.D=+-3.-2>=2.7+22A2=<012<9+17.7817:61<L18.7835. ;6917-:+*.<+253,2-+,.9.G1-.37A ;146,+*+7-)*+,-./5,3 ;:+9.*+,.78.-2:+*.<+2371-. ;+94>12.2? ^& [cd^’e&[ ()*+,-./.22=>I+<--3+/-+72.*+<3 ;69.17<+,+D=.,+ ;+7-253,-0+D=19.-435-0+B=1,:.17C42-+ ;.- ;17=51<-=,+217:53,*.8.917<+37<3 ;691.7-M017:9.78A+2<191-.37A122+22 ;+7-A17:,+63,-.78351:*+,2++*+7-217: ;195=7<-.372?)E.:+,178+35D=19.-4A,+8=91-3,4A3,215+-4 ;1--+,2<3=9:-,.88+,-0+7++:53,1,+<1993,<3,,+<-.37-3 ;1,L+-+:6,3:=<-2? (K5)*+,-./51.92-3<3 ;694 E.-0 ;+:.<19:+*.<+A0+19-0<1,+17:3-0+,83*+,7 ;+7-19,+8=91-.372A.-<3=9:51<+2=>2-17-.196+719-.+217:.-2>=2.7+22A,+2=9-23536+,1-.372A17:5.717<.19<37:.-.37<3=9:>+1:*+,2+94155+<-+:? ()*+,-./F2<3; ;=7.<1-.372 E.-00+19-0<1,+2-1L+039:+,2 f6042.<.17217:3-0+,0+19-0<1,+6,35+22.37192A6143,217:2. ;.91,+7-.-.+2A12 E+991261-.+7-2 f1,+2=>I+<--310.80:+8,++352<,=-.7453,<3 ;69.17<+ E.-01E.:+,178+3591 E217:,+8=91-.372?N37-.7=.783,.7<,+12.78 .-2219+217: ;1,L+-.7817:3-0+,+/-+,719<3 ;;=7.<1-.37+553,-2 ;14+/632+)*+,-./-31::.-.3719,.2L35>+.78199+8+:3,:++ ;+:-3>+737M<3 ;69.17->4,+8=91-3,4A+753,<+ ;+7-1=-03,.-.+2A3,<3 ;6+-.-3,2?


    ! ! # $ %$&%’ ( )%(& %% % ( ’ !( *’%+, -) % .% % !%%& % / *’%+% )-0 &%’ (! # 1 $’1!!%.) .% ! ) &%1 !12! 1& !% %1 %!! . % %!) &!( #%11)! )-0% )- % !!% -%!%% .%!)%$&%’ !%%$ % 3 ’ &)-!%%( )!$ %’!( % & %$ )! -) % / *’%+ (- )-0 ! ! ! % ! # #1%1% & )- % !& !% / 4 5) !%(% ) % #%1*’%+, &) )! ’ !( 1 )! % & % / 6$ %’&)-!%%(%$)&)) &% ,&) .%!)%$)&) ( )!%$!%%$ %.)!1 )&) % ) 1 7 # %$ ( .%1 #1%1)! ’ !(% & )- % % ! )! / 8*’%+% )&&!% %! &!( #%119 4)$* %% %, :1;94*<=$ ) )%$& %$)! % % %! % % !$)! % .1% )!% & %% -%!%( 7% &) % 2%’ %!( / 8194* % %! $)! ( )1%( &&’)))&) 5)% %% !!%% !% ! - ( &&’ !% ( &&’ !)&) %!) %% ! %% 1! -!.5)% 1 %> %)&) 1 % ) 31$)! ( )1%% .)-) % .% % !%%. )! & % $ #1& & )! - % !!( ’ !( / ?@ABA?CDEFCGFHI JK@KLFMCNH OP@KCGNH OQEKRSATFHUB *’%+1 %%% % ! # 7 %)% !!’% % !&%$ #1%1.%.)! 1!% -%!%(1 -% & (V % % ! . 1 ’1 ’ 5) / 9!!#%$1! %$1&% !-) % -% %. %’ %$ 71 -% & (, 7 (- ’ %! -! % - % &’% 1 1! #%1 5) !%5)%%(/W1 1 &% (-+!(’! %! 1 1! )!! %$%% & 1%%’ / X ! )- % !) - 1 1 -% & (, 7%1&)-!% 7-(+% %$ 1 1! )! ) 1 -% & (, 1 &%!%/ W1 -% & (, 7 ( %!1%%% !%)!% %$ 16 5X7 Y 7ZZ[:;6 5<=. %% ! 7 (- &&’!% %$6 5.!!#%$1! %$1&% !-) % -% % +1 $. #1%1)!!% %%’ , -%!%( 7 % %1[ & (, )%% )-01[ & ( %% ! %$ %% / \ ) *’%+1 )&! & ( 1%’% 1 -!)).() (%’ ()%’ )! () !!() 1 &%$ 1 #1%1()& %1/ 8.!!#%$1&% !-) % -% %. )%% %) ( !( &)-!% 1 &)-!% 1%$& -)1 -% & (.% -) % .% 7.%1(1 $1% % $ %$1 -% & (, )%% ’ !(. 1&% %$’!)1 -% & (, )%% )!!%/ ?@ABA?CDEFCGFHFMC]^HQHACG_‘A@KCAANH OP@KEF@HK W1-% 1&% !-) % -% % (- !%>1+)!( %%& -(\8aX *’%+. !!/W1 -%!%($%> ( )1-% (- -(. $11%$ . &%%.1 -%!%(1 -%& ( $ # $$ #1&% -!(. % %! % 1%& #%1) )&&!% %% $ 7( &!( / W1 ! 1&% !-) % -% %)!- %$%% !(1%$11 )!( %%& (+1 ) &% ! % %% #%11&% !-) % -% %/ 8\8aX ) %%% !-) % -% %-(b)c.dedf:)! +)&4 -c.dedf )!1 &%1+ % && ! 1)& %$+ %%$=.% &)-!% 1 1! (- # %)%! 1 - &%1W) *)/ W1 ) %1&% !-) % -% %% +&- )-0 ) -%% .%1 %% % % # %’. (%%%’ $! %$1&% !-) % -% % (- % % #%1% 1&% !-) % -% % (- &!/ \8aX% % (1 ’% %1&% !-) % -% %%1% \8aX.*’%+1% &%’ )%(1! / W1&% !-) % -% % #%!! )!%1 $ 1- % *’%+1 ( 1 $(1 -% & (/ \ ) 1 -% & ( #%!!- &)-!%!( & (-(’%)$ %% #%11&% !-) % -% % && ) #%%%% !&)-!%%$.1 ) #% %’!’%1& . #1% 1)! )!%! %!%$-%$)1W $1 % ) #%%%% !&)-!%%$/ W1 -%!%(\8aX, 1 1! +% &%%$1 #%1 &)& !!1) %$\8aX[! *% ( 1 )!% 1&- -%!%(1 1&% !-) % -% % #)!).%% ).!% %1&% !-% 1 &% !-) % -% %.1 1-) % % % !%%1 -% & (!!#%$1&% !-) % -% % 1%$11% 7 %$1 -% & (// W1X[1 !(% )&& )! Y 1fe.dedd:1;Xg*[h)!g& ! <=! %$ % %’%% &% !&)& 5)% %% & % /[ %1&) 1 \8aX. &% !-) % -% % $1 ( %) 7 %% #%1 )1&& ! (% \8aX, 1% &!% %%% !-) % -% % ( %1%) ) #1%1\8aX)! &! %%% !-) % -% %/W1 &!% #% 11Xg*[h)! g& ! ( ) \8aX!%5)% 1) %1W) *)!%5)% \8aX !%%1 \8aX %$11 #% 1 / 8\8aX% - %’ & ()18’ [ & (*.\8aX (-5)%% %)-) &!% 5)% % %’%% (- %. #1%1 ( 7%%%)!\8aX &!% %%% !-) % -% %/ W %%$ 1% 7-%$- %’ & (&)& 18’ [ & (*.\8aX (% )) 1W) *)!%5)% 1 )%% 1!%1W) *) % 1! !!) %1W) *)% - 7& % )/


    GH I JKLMN^\HWH_GK I^S‘SLaWHM 1&# - 301 #b( % 34,%(+, ,)+,+, 3+- /%&;97)# &5<&#=> /+:6 1 ,*)-34*)5)1.* &6 ! #$%& && 1&# - (:,5?3>:36 +-7%#& /8’()* +,-.,%%& /#,) ;)@)01A; /-(# B /# , 9 (& : -9 & 1 & 01-$ 2 5<C3> /’:6 OMPHQRSSNMNVKWWX YHNQWSLZM[\M]K\N^\O :, ) !01;)@), , +, /2 +, TEF!& U.(4 #()* # 01- % , &-?%,7) DEF!&4* , &&,)B) , #*)! :;%# !& 01- /2 A % , &-&&&& @) ,)& )& ’,- .,%%& /#,) ) ,) &) ,%& 3 -.:A:B$))?@& $ #A1#%,/2 -$ 2- !&)


    ?@AAT@UCGECU?@UC]^ H BCDEFDECG?FDVW_CAG ‘CU #$%& ’$(, K+ O%:3 #$%& ’$( *+, 5+ ! #$%& ’$() *+,-&%./(012.3 ’2 ! *+,I3J/>/K%/.#3&$=36.%:2 !03(%/&X7J%2/&,* YZ3$>.#:$&3L$&.(3&2 ! /45/6(73&, /&3-389(:; !5/& ’3&L&32%73(.,M(%.37-#3&$=36.%:2 !5/& ’3& *+,[3&/ ( /&=/&$.%/( !<%&3:./&, #%(//8-#3&$=36.%:2 !5/& ’3& *+,0.3$71 N3 7-#3&$=36.%:2 !5/& ’3& *+,I%($.\36&/2:%3(:3 !<%&3:./&,5>63(:3 /&=/&$.%/( ! /45/6(73&)5/& ’3&0OL/PK<,Q/R3(%S !<%&3:./&,06(3J $N37%:$> bGcdEcUk@lkCUDcg p]cUbEC fU bEce fFUg hiji hijigmEiji pF@qCUUcGGFte@AA <%&3:./&<%&3:./&<%&3:./& <%&3:./& !5/& ’3& #$%& ’$() *+, 3>>[3(3212 !5/6(73&)5/& ’3&<%&3:./&, $&7%/[3( !5/& ’3&[>/a$>K%/.3:#,n%P30:%3(:3 !L&32%73(.) ++,X==;N/>3:6>$& !5/& ’3& #$%& ’$() /45/6(73&,0:%3(:32n3$73&,*o-&$(2=/&. 3&3R3(3 !5/& ’3&*OL)0&;X7J%2/&,[%>3$7 !<%&3:./&,I3J/>/K%/.#3&$=36.%:2 !5/& ’3& #$%& ’$(r *+,[-K%/=#$& ’$ !5/& ’3& #$%& ’$() /45/6(73&,XaR3(%S !5/& ’3& #$%& ’$() *+, O-#3&$=36.%:2 !<%&3:./&,-3/ (-#3&$=36.%:2 !5/& ’3& N<, /4Z3$7Z3$>.#:$&39K,s NL uvI/22Z$R#%R#$.wK9+0 *+$(7 5+,$(7XJ3&.%Sx2*S3:6.%J3 #$%&v#$2&3:6237#% ’23>PP&/ ’73:%2%/(4 ’$8%(R/(.#3.&$(2$:.%/(/(K9+02%73R%J3(#%2&/>3$2*S3:6.%J3 #$%&’$(/P .#3K/$&7/PXJ3&.%S;5/&$77%.%/($>%(P/& ’$.%/(&3R$&7%(R.#3%(.3&32.2/PK9+0$(7XJ3&.%Sy27%&3:./&2$(7/PP%:3&2%(.#3=&/=/237a62%(322:/ ’a%($.%/(,=>3$23&3P3&./.#3z9 ’=/&.$(. 9(P/& ’$.%/(P/&9(J32./&2$(70./:8#/>73&2z23:.%/(/P.#3<%2:>$% ’3&/(2>%73{;


    \ HIJKILJMQRSTUVKWXSWYTLRXH MXJKSZL[ N1$7$ ,$ 3$$ j:i21$ p6 3 62! 9>G& 4’-G/*O’0. 3$ <-’8 NP 44 90(6:6. ./4+3 / 2! ! N./ !!’(’% 6:6.:3 %G-’8 %-?8 N./4+3 /2! ! 4((8! /4@$7 j:i26$, G 2! ! %0->8 ]XTJK[KLSJ^W_‘Jab ccdeR‘KYJSWXfgSJSab ccd ]XTJK[KLSJ^W_‘JhW_Y‘_WTLRXeR‘KYJS 2! i$4A%G-<j:i2*!P $9%k ’ 6:6.6 A/2! 6 9(-((0( % ./4*!j2! .@$7C$9%G< < .@$73 ABl*!AGk%’ . C$9>GP2$ 9%’ VKWXSWYTLRX m‘_TL[_JSgSJS 0 *!j2! . C$n’(’<.3$G-(/9Gk G . C$n’(’0.3$’-G/P *’ < .@$73 %’ Po9%’ ! #$%&’(’%)$*+! ! !!,$ ,-./$-01$ 2! ! ,$34$,5!!3 34-6 47$ ((8$ $4-’+$90( 46:6. & !!!3,! $,$! -%+3 /;/4!,! #$%&’(’%-<=$’->? $! /4+3 /@$7! ! $,534,4!3A0(8’(B7C D+69’-0(0(8 ’(B7C D+690-((&7?7 4,$ ,4-0+$*+! !! ,$ ,&E90( 6:6. &E9’ B / &!/4+3 /F! ((8! @$7! 7-G 7-


    ijklkmnlkonpqrplsjk tspukrkolrvwx N:NG P635QA*40A-R S ! #!##!$%&’ ()( &+1yY 9)H ! #!##!$% ! #!##!$%& &’ ()( & f=-0z:{ G)H’# & 8 *+,,-./-0+-12-31456-0 30-A+,-15 36-305355327AK0=+=40 8 6-305355327 9 |} ) H$ &!& $HF ( H# C9 9:; ~ ! & %)H< I 0-3A41>40DE!F G)&&)HJ !(<:’ & 54300+=->40 ?-@+23,3,564KL6MNO()&)#&! kokprq B +15-0=-15+4135364A/+53, H ’& ST655/AUVV ***WAK0=+=40A63=-6-305W24 ?VA535+A5+2AX31@X0+A7W65 ?, 8T655/AUVV ***W2@2WL4=V6-305@+A-3A-V>325AW65? BT655/AUVV ***WA2+-12-@+0-25W24 ?VA2+-12-V305+2,-V/++VYZ[B\SZ][S]B[B[^[_=+3‘Ba+6Kb ^T655/AUVV62K/XKAW360cWL4=V0-/405AVA535b0+->AVAb8deXfaXg0-cK-15Xh41@+5+41AX8ZSdW/@> \T655/AUVV ***WA2+-12-@+0-25W24 ?VA2+-12-V305+2,-V/++VYZ[B\SZ][S]BZ8B[8_=+3‘Ba+6Kb


    B0CDEFGHIJKILMNOPQHRREKSTJD URLHIGHVLTWHEJDHW UKIDGKEDIX)(: \]^ HLTEGDIX!&) >-*3:0 ’,(0:>-* 0THELMJTGTWGDKIKCYTHEGHGGHWZF[ _‘) 0( 0:)(:!*-!*’0 )*8)&,-*’ 31 ’(, 3)%’(0 &0)*(’(,a )’&-*0: - 0’(:’.’:1)&!) ’0( _/b$c$def%-( ’(1-1 %)*:’)% 3-(’ -*’(,;)&0* _=:0( ’%)&!*-%0:1*0 - ’(,&0%) 3g0*!)%0 3)h0* _ij5)!!*-.0:;7 k9*0’ 3g1* 0: _l0 0*j0%’ ’-( ai) 0*+ ! #$$%&’(’%)& *’)& +,-.$% /$*0 1& 2 0* 345%1 067-*-()*8698(:*- 306:0.’%0;),0<.4;,(:*4; 8!04=( *;* & 4;90)*%45!!&8 /= 3),0->:0.’%0 - ?(’ )%- 3!1 0*@,0(0*) 0:’ 3),0 ) :-0 (- *0!*0 0( 0)% 1)& ’A0-> 0:0.’%0+


    WXYZ[\]^_[‘]Xabcd\e^b[‘]fg c‘]hi . ! #$%&!%!!%’( )&**+& ,- /%’$0%&12232224567868869:;3+< =$’$1>223222675 AP ?5@3% BCD2E+<!$ F%! ! %&5GHIHJG5KL7MN67OH6? kj j Q$RS&F& ! %CTUJHGGHL?6OO75;;6JG5 V67:58 l,-)F!+mnop!$ r q+<,-lFF+&!) !0 .s$!!F tuu ===o )&**+& $%*$%&!o’+v As$!!F tuu ===o’B’o#+*u$%&!B % u<%’! o$!v wsx% B+ v% %#v !’%y’)y%!+ !$%!%FF&+ v%!y0.z{+< B*B)%y =$+ )<<&%$%&!%!!%’(&’*% vFy% !B|}~ rsl,- v%&(! qB%!%% +<Az.$!!F tuu*q$)o$%y!$B%!%o+&#u#B& )y!


    ! #$% &’()*&+,#(* t( uv ww#*xt( uu yz#+w {vv(y,)*#,| -./001123456789::;;;79<=>9?@AB>?A -ED2S506625OODFG5 ]D2f5Q -C23D6EDF5G;H=>?9I>JH -gJUh:I‘DG5O‘Q2DQ5SXd<JiA?I>Hjklm ]K54LPnm -K5LMFN2O5 M5PQR3452DS5 -o5DGQWXp23OO ]D2SLPO -T9BJ<9U8 AVWXOLYLDPZY3P3 MLYO -q8JU98K545PN5‘Q2DQ5SX -C23D6[VV23Q5YQL3P -d89IeJ< aZr1DPOL3PK3D6 MD1 -\I9U8A ]DPN^DYQN2LPS_‘N11GX -V2345PE5D652OWL1s5DM -; ab8A aAHI9I>JH\> a>89<IJ7J aaJH8c dA<eJ< aA=V23Y56N25 }~d<JiA?I>JH:9::h aAh8c?8J:A


    ! #$ % &’ 6 ()*)+, -,*./012,3.41*5 789:8;<=>?>@A9 B<>@CDE {|}~| || 7F;<=>?9>E@GE?89:8=@A9HIJCCK 9==@>8LM BN:9>@AOAHAOP>A89? Q@8<E>9:8RIE=A98EH9?@<>E@S <A@?=>EE>O 7TA@U=>E@8988BE B<:9>A@V AE BNA89N:WI@:O 7TA@U=>?89:8@V9<<A@;E B9>:OJDNO E=:?E H@: O=@>A9=>??E8>AEN>E@ 9HA B>8EXFYM9?M8E9T9=L;ZP[E9R 7\]^_‘abcdeff D^dghifj:?NOkTk AE BNA8B>9?>[@H[>V: B9V9=>AEH <:9 z 7>A@H<F ;VVE=E=E89?A@N8>HA@88 B9AHE F FF 9A;<=>?>@?AE>@lmnopqrefh‘hs]hiJCJ 7M>E=E<9>tCDE=9<E>9:A9E8?AuEA?>@ A9=[v^faw_e xrefh‘hs]ybJCJ WRTA@U=>E@8988B:O=:@8Z



    Q KgH>BJ>hHC V !% # GNODIPQ =N ‘ $ $#’# !’#’( !% # ’% 2’ # !’ O RS ‘_ # #$ ’%* #* : # !’ 7’ #)# ( #)]#(LNPN RPQ TU W $ %’#$ XYZ[0 \ NbJCEB>HGC?CAcCE =>?@ABCDC>EBABF ‘)!’(# #( !a* #$#$ ’% :)#’!7 ^6 ! # #$%! &#’( #)& ’$# ’ ’%!)!’ ’!$ !* ( 7$#’# !’ ’#]+ ‘.’#:$# ’! $’)#$# ’ #)# ( #) !’ ! ’%!+,-%’ _)! #$_!)< fEMFE> KKCE GC>HIJA KCLCJC?JAMB ‘ W $$)!’ )# d && $#’ .* /0)!’(123456748# ,-%’#’()!# !## ’9 +! # # ’%#’((## *#$ :#$ ’ ;’! + ’%&# ’ ’ #$- !< %’)( )#$#’ !’ ‘6 $#a#’#$e! ((##


    ! # $%&’() #*+,!&#- 0123454676338338396:487:;3 $ ./,/- 7<7=>?@87:5<7A4:4<7 PQRSTURVWSXYZV[ \]R^_ PQRSTURVeTTZTfZVZgU_h a B‘988A<MA46@7<343 G BC63:8?:4 D8:<EF a B‘988A<M?8K635>I6?4b6:4<7 J BH32 D9:< D6:456I8?:3 a Bc8A>58A47M6?5:34b8 J B0<34:4K89?8A45:4K8K6I>8 a Bd8::8?I<7@4:>A476I<>:5< D83 O BL>6I4:2<MI4M8N98658<M D47A a BH??12:1 D46A8:85:4<7 Gi1::93jNN kkkl3548758A4?85:l5< DN3548758N6?:45I8N944N‘mnOoGmpnGpOnOnanqK46rOF41>s Ji1::93jNN kkkl3548758A4?85:l5< DN3548758N6?:45I8N944N‘mnOoGmpnGpOmJOnJqK46rOF41>s OiHtEcu‘L>6I4:2=vM=t4M8wHLvti‘>s=3:>A2wx< D9672‘:>A2iy1::93jNN kkkl655833A6:6lMA6l@<KN5A?1zA<53N9AMGoN0Gommmpxl9AM aiL>6::?<{>6?A467{?< k:1v99<?:>74:2 |6?}8:‘:>A2wx< D9672‘:>A2i


    0 123456789 1:;56;<66=>6=?:3=5@5534AB '5“:= «‹97943‹›97fi97flB S- †‡&( †w+x+, † +* Ovw–L S’x )& yz{*# & %& # †(, ‡, #’%&’/ &N+)! #$%&’()’) *- †‡&( †*+x() ~(, |}v (~&(&+x$)) % **+,-.!/’*’&* , +x·RS / )& !.PQR.S ” ¶•3‹95‚6>„9>:0 12345 TUV WXYZTUV WX[Tfghij WX[ \]^ _‘a _bc^ _^d‘ec\]^ _klk]_ Uf mhnouqj pqrstfriUf mhno pqrstfri CGK EKJEHKJFCFCFFFGI DGK EKJEHKJFCFCDFDGI L I¡¢¢£¡IKI£⁄HI¥GK EKKE¢EƒHJG§HK¢C¤C⁄E¢ C CDE FGHIJK C LMN($,* C LMON($,*



    VWXYZ[YW \ ]^Y_W‘abcWXdYWeY_Zfa^VWXYZ[YW \tbb‘^_ac‘ucebvwxww ghJRSSJQ #$%& ’(&))+, O6<0=4(2+&15%;(:06/, #7&(80%9/424(.:(&/50;&%4(/.1$%G5%44%H i(65=%4%j0(/,).2(==( O(:06.4 !! kU0/1&[email protected](/ O.=.j(&lro #$%& ’(&)*+,-.&/0123(.4156.&( k)40=06.4lso #7&(80%9/424(.:(&/50;&%4(/.1<90:.=1>?%/1%=@60(=10A06, @1BC9:(>DEE%11,?0%1&%=0F,.=:$%G5%44%H I JK L!MJ VWXYZ[YW \tbb‘^_ac‘uy^Yz‘Ye{|ucebv #$%& ’(&-7,N@@.4(/,D6919/ O(:06.4 #$%& ’(&-7,?0%1&%=0F }~wxw~ P QRST #$%& ’(&-7?9/0=(//.=: O.&F(1U(8(4%; ’(=1, D6919/ O(:06.4.=:-%46.=%)%&;%&.10%= kU0/1&[email protected](/ O.=.j(&lmno k)40=06.4lmno kp=:(;(=:(=1/lmqo


    tuZ\TSTU^XOtuZ\TSTU^aQbQRRUV [O\]TXUVU^_‘WNaQbQRRUV\ c9C:C@>L98=C:de D;?89=C<f+1g!+J($h+!-&’#)0J%1#+#.1%& /0#0(% !i)!’&1%!1$H(-! (g!’%j3 )+($&(*+!k(’,1(- !l1*’1++(&#’%F3k %Gj !&-m1$&0!)’(-&1-!m NO PPQRSTUVWXRUXQYZ ! #$%&’(&!’!)!(&(*+!($,%-(+(*+!.’# /&0/1&0)’!,1-&(*+!’!%2+&% 3 )+! !$&456789:;8<=>8?@;ABC DA:C?EF-#$&’#++!,+(2$-0G /1&0nCKC<<C<@opqr01.0s#+Hk3I3k% /0#*!+1!s!($,’!l!’&#3 )+($&!’ H’!-1%1#$I-#$&’#+())’#(-0&0(&J1!+,%498=6<8?<CKC<<>9LCM;89@>A9@E


    ! #$% %& &#’ () % ) * +,-./061780 +,-./01231 452+,-780129:;<52 =>?@?A>BCDEKLB MFNDE?OPDCQFO?BGOR SLDBTQBE?BGUBFGVIW\FO?BGO?R MDEB FGHIJAXOFEBRBGOLD MB S?OLGDDE>? M?OBYOEBFO MBGOROFA?>?]BYAXO K[ UFGGD SABDCCBEBYFZXFEY?FGRO?>>FOE?R^ _‘a bcdeffgehiejkj


    A ; 9: *H4. 7I5,64748>J18+ 7.36 ’() *+,-.(/(012,(34-5,4624,)(, 74-.89: *6 Vfgf]MN#_#NVhghO^ MTRijKjSROUklmll nMW#NMo__&MRV S[TR%kmp qrstuvuwx yrzs{|}~ jPOT&#R#STOUhO&&%jaPS[XahO^ MTRRSVWMPR# ‘ig Kkm &R# ORM$ ]UOTRMPYM# Z[P&M MTRk %km ! #$%& <,( =>?;@ABC>?,(50? 7.-D;@;@6;F’ G’ <,( =>?;@AED;@ABC K LM$#NOPMQOR#STOUVWMPOXMYM# Z[P&M MTR\YM# Z[P&M MTR&[]]SPR]PSW#$M$Z^P$]OPR^O$W#&SP^_#P OT$_[T$M$Z^VWMPR#‘\ KaRR]&bcc ddd\ZO#T\NS c#T&#XaR&cO Z[UORSP^%&[PXMP^%NMTRMP%XPS dRa%ONNMUMPORM&%#&% M$RMNa%PMO$^ce


    6 &’()$ 1!) 2-#(! !%$34% )5( ! #$%!#&’()$ ( *+!#!,-#.)% )(/#’0!. [EOQ<D>G\Q:=<S<=H]^]>R L:FD_A‘@‘a8aED>Gb7AcB@d e:I<=:fSSO:DH LENFDYbgc@hi jklmnonpq rksltuvw a?>FO<D<EF>G]>OOYaU?ENJU]>R L:FDDEHI:?D< T_^7gBB8b7Ac@‘A xOD< L>D:;y LQG>FD:?K:< LMN?O: L:FDbgAAYb7c@AA 78 9:;<=>?:@A@BC>D<EF>GHI:?>J:K:< LMN?O: L:FDPK:< LMN?O: L:FDONQQE?DQ?EI<;:;MRB?;Q>?DR>;I<OE?RS<? L>F;SNF;:;MRHI:?D<TP @8UDDQOVWW XXXPM><FP=E LW<FO<JUDOW> LMNG>DE?RYON?J:?RY=:FD:?YJ?E XDUY>==:G:?>D:OY<OY L:;D:=UY?:>;RWZ


    ! # $%& # $% ’() %*++%) %, l^‘iv[a[ f[] VWPNMKNLQ WXPQRNQSFGH IJKL IMKNO FGH IJKL IMKNOJMKNPQKG WUXPGULR JMKNPQKG RNMSQLGPRTNKU x E94 E. <{ RNMSQLGPR qMXRNMQFXXHKU INM TNKUVW [w[c^m^b]\s[ \m^iv\mt^\]^ecs]b fijj KXPQRNQSY \^e[c^m^‘[c][a[ew[g oMKNPQK _‘\cs[ectu Z[\]^_\^‘ MMKNLQ^][\^ f[c^ pq rG v[we\^ebc abcde] f[g x y@;<:z?{ | -./012 3456 |} he^‘ijk 728.9:.;< 612<=.</ l[mebc\cg >.?:;/19 @9<= n\^e[c^h\m A;112?B;<=.</ CDE GKPQKPR ~j bwec s~ws ~j \ ~j ec \m^iv\mt^\]^ecs]b fj ¡_bcga^[ga\m[m^ge[m\][ab fn\cdcg[g \ [ge\c tuv[we\^ebcVW e c[ge\c t uv[we\^ebc PNMKNLQ t uv[we\^ebc


    B8796857<C85DE76579FA 4567896:;<=>?7<@<7A GHHIJKLMNOLOPQRSN ! #$% & ’( )$*+*+ !% .#$ GHHMTULOTJVQ , - % & ./0 GHHIJKWX ^(# *+*1 0 ’_# /#$- ’( /23( ‘ % % GHHMTULOTJVQ ) %a % SVXWIYWKWMJHZWVO # ! GHHMTULOTJV 2/ [MLVVWXTV\] /2



    ! ( )$*+,+- ./0123245621271 #! 89 :;79.472957 <;527;=25> #$%!&’ ?474@4A7B=945C <;5972D472;5 ‘aA45C9CbC;A74c2d270 EFGHIHJIKLMYZXIL Q[\HSI QHMI]USMXSMT ^ _ GKSWMLXIKJX NOP QRIL QSIKJSMTOKUHMIVYL QRUKSMJH


    !%& ! #$ , #-( ./0/1 0+2$*3*4*$* $ ’ % #% 0 * 5%* %*) ’()%* +# 6 7- 5% *8 *% ST-’%- *% 9:;<=<>=?@AMNL=@ EOP<G= E<A=QIGALGAH R$7$$;?GKA@L=?>L BCD EF=@ EG=?>GAHC?I<A=JM@ EFI?GA><


    ! # $ $%&’’()** +*,-’;)3)/2=’.;A +71173, @ ./0*123)4*%56/,173,8 %B$=9.;A +71173, @ 9*:*,;*9/ +6 &*5-<%&’;)3)/=*17(,2)**>* %B$=9’66)3:/0 @ $%&’9*(;0/-3)?’66)3:/0&*5-<%&’;)3)/2=’’66)3:/0 @



    ! #$ % &’ 6 ()*)+, -,*./012,3.41*5 789:8;<=>?>@A9 B<>@CDE {|}~| || 7F;<=>?9>E@GE?89:8=@A9HIJCCK 9==@>8LMN89?O@8<E>9:8PIE=A98EH 9?@<>E@Q<A@?=>EE>R 7SA@T=>E@8988BE B<:9>A@U AE BVA89V:WI@:R 7SA@T=>?89:8@U9<<A@;E B9>:RJDVR E=:?E H@: R=@>A9=>??E8>AEV>E@9HA B>8E XFYM9?M8E9S9=L;ZN[E9P 7\]^_‘abcdeff D^dghifj:?VRkSkAE BVA8B> 9?>[@H[>U: B9U9=>AEH<:9 7>A@H<F ;UUE=E=E89?A@V8>HA@88 B9AHE9A z ;<=>?>@?AE>@lmnopqrefh‘hs]hiJCJ F FF 7M>E=E<9>tCDE=9<E>9:A9E8?AuEA?>@A9=[ v^faw_e xrefh‘hs]ybJCJ WPSA@T=>E@8988B:R=:@8Z


    ! #$%&’(’ !# ’*! 0 $*. )’&’ &+,-&(.’ ’/! 1#1(/2*9* / * ’*! 9* / * ’*! R 6.*/. ’!:6 /!’ /.’!:; /!’ /.’!:G’ $ ! % ’(& </,!2($*(=64>2 %(,& / ’H -* !2?6@647A /! $!/ ’I’( ’/!& ($*(=A,&B *. A2.’C*!+,-&(.’ ’/! 4 /’! *! &JF *; 3KKD L/M@N* .& 3456785*.#$%&’(’ !DEC*. ’FO3PQ*. ’*! /IS,’2/. . !*. ! .*C*!,*&$ .*.*(,..’!:.*C*!,*/2* /C*.’I*/I’ ! TUVWXYWZW[\Z ]^[^_W ]W[\WZ\‘ ]^\Wa


    ! #$%&’()%*+ ’) u’ vwxx )yu’ vvz{ *x |ww’z+() +} ,-.//001234567899:::68;<=8>?@A=>@ ,DC1R4/5514NNCEF4 \C1e4P o ,B12C5DCE4F:G<=>8H=IG ,fITg9H_CF4N_P1CP4RWc;Ih@>H=Gijkl \J43KOmnl ,J4KLEM1N4 L4OPQ2341CR4 ,p4CFPVWq12NN \C1RKON ,S8AI;8T7 @UVWNKXKCOYX2O2 LKXN ,r7IT87J434OM4_P1CP4RW ,B12C5ZUU12P4XPK2O ,c78HdI; ‘Ys0CONK2OJ2C5 LC0 ,[H8T7@ \COM]CXPM1KOR^_M00FW ,U1234OD4C541NVK0t4CL ,: ‘a7@ ‘@GH8H=IG[= ‘=78;HI6I ‘‘IG7b c@;dI; ‘@<U12X45M14 ~c;Ih@>H=IG9899g ‘@g7b>7I9@



    @A B CDEAF@DGD =\b LMNMOPQ RMST<) =; \ ( )*+ ( )*+ ]I^^ H-./ 012345678&,-./ 012345678& _:‘a ULVVQQWPNVOX >’ 9> YP RRMWYZVOZ[VTZPS ::;IJ; ! !#$%& =K cde3f&%$4gh&.57i 0343j& 0&45&f57 035&fk >?


    MNOPQRST UPVSWXYZ[\W]^_NOPQRST‘aX\VbScdYefNWgeSfSRSc\hcQi]Z^_b[jk‘a^ lNkmN nob[jkaRcWc pqS\PRcWQPXR PXieqYSWYrYSfRPV ^wa Wc piX\ rsSR tX\eiRcuvwxy ppP\RPQiQSf POXYeP MdcfRzWYcfS\ {P\RSR rPTiPWRP VRcq PYSfRP Vc\lNkmN ne\VPQ\PsRSW|PQZN}~ZX\VpXS\RXS \RtPNOPQRST\X pP MtPRQX\fXWRSc\SfPTiPWRP VRcWYcfPS\RtPfPWc\VtXYc ^a M[ piYSPVP\RPQiQSfPOXYePc]yTQPOP\eP ^a MTSfRS\{NOPQRSTPgeSRrtcYVPQfsSYYqPSffePVXiiQcTS pXRPYrw] ppftXQPfS\\PsNOPQRSTftXQPfcQNOPQRSTciRSc\f ^a MQX\fXWRSc\RcqPe\VPVqrXWc pqS\XRSc\ceiRcXiiQcTS pXRPYrvw ppb[ jkWXftS\RQefRX\Vv ppcPTiPWRPVd[d iQcWPPVfQXSfPVicfRzX\\ce\WP pP\RQc pS\fRSReRSc\XYS\OPfRcQfX\VfRQXRP{SWf ^a MNffe pS\{\cQPVP piRSc\fZNOPQRSTSfPTiPWRPVRctXOPvwy ppS\WXftc\SRfqXYX\WPftPPRiQccQ pXcQRtPRQX\fXWRSc\Zc stSWtuv ppSfPTiPWRPVRceYYre\VRtPWc piX\re\RSYiQcPWRPViQcSRXqSYSRrS\ Mb[ jkh j~cffX{tS{tXRSfPTiPWRPVRcqPNOPQRSTfhtXSQ pX\cYYcsS\{RtPWYcfS\{cRtPiQcicfPVqefS\PffWc pqS\XRSc\ MbScdYefkic\fcQhRc\c pS\XRPRscmSQPWRcQfRcNOPQRSTbcXQVcmSQPWRcQf MTiPWRPVbcXQVcmSQPWRcQfo pP pqPQfZcstSWt pXcQSRrXQPS\VPiP\VP\Rf ! # $% &’( )$*+#$$, ) -,(,$.,!/$,0,, 12,$%3(& 45 )) (,! ,+$,$*’6 ,$+7($,8!3 ,!, (9:%,,6,$* )$3,9$*%!$6;<=,&>8? @’A.& <<=,&>8? @’A.< B8,$ )$58 .33C$*,!%3$*.,!9($%)9$,$ D ’.E(1B&&1 F,GH. ,, %,$( )) 8#*. .( ,! ,$3 <’( )$,$3I3’! )#,$$%%,$ C$,!,!#,,$39($%)9$,$B J<)).AKAL# % $BJ&))., %,$> 3,+#B,!,+$,$*’6 ,$+,%-!3 33=.,!$ 7($,8$,,!# . ),$,8

    Get the next $BIOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors

    Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&A Expertise ReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. Howard Berman, Ph.D., executive chairman, stated: "Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital,

    1/7/26 8:00:00 AM ET
    $UTHR
    $BIOS
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Blank Checks
    Finance

    BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate

    New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. ("BIOS" or the "Company") (NASDAQ:BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the "Business Combination Agreement"), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company's initial public offering ("Public Shares"). The Business Combination Agreement was dated as of May 2, 2023. The pa

    10/4/23 7:30:00 AM ET
    $BIOS
    Blank Checks
    Finance

    Avertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business Combination

    EATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) ("BIOS") (NASDAQ:BIOS), a special purpose acquisition company, announced today that the two companies have mutually agreed to terminate their proposed business combination. "While we were enthusiastic about the potential business combination with BIOS, we mutually agreed that the current market conditions are not co

    10/4/23 7:30:00 AM ET
    $BIOS
    Blank Checks
    Finance

    $BIOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bioplus Sponsor Llc

    4 - BioPlus Acquisition Corp. (0001856653) (Issuer)

    6/12/23 9:17:36 PM ET
    $BIOS
    Blank Checks
    Finance

    $BIOS
    SEC Filings

    View All

    SEC Form 15-12G filed by BioPlus Acquisition Corp.

    15-12G - BioPlus Acquisition Corp. (0001856653) (Filer)

    10/16/23 4:15:07 PM ET
    $BIOS
    Blank Checks
    Finance

    SEC Form 25-NSE filed by BioPlus Acquisition Corp.

    25-NSE - BioPlus Acquisition Corp. (0001856653) (Subject)

    10/6/23 4:03:10 PM ET
    $BIOS
    Blank Checks
    Finance

    SEC Form RW filed by BioPlus Acquisition Corp.

    RW - BioPlus Acquisition Corp. (0001856653) (Filer)

    10/4/23 7:39:57 AM ET
    $BIOS
    Blank Checks
    Finance

    $BIOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

    SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

    2/12/24 4:14:06 PM ET
    $BIOS
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

    SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

    2/9/24 10:26:34 AM ET
    $BIOS
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

    SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

    2/7/24 2:00:23 PM ET
    $BIOS
    Blank Checks
    Finance

    $BIOS
    Financials

    Live finance-specific insights

    View All

    Purple Innovation Announces Cooperative Framework with Coliseum Capital

    Company to Welcome New Directors to Board Adam Gray to Serve as Board Chair Gary DiCamillo to Continue to Serve as Lead Independent Director Company Will Redeem Cumulative Voting Proportional Representation Preferred Linked Stock Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple" or the "Company"), a comfort innovation company known for creating the "World's First No Pressure® Mattress," today announced that it has entered into a binding Memorandum of Understanding to establish a cooperative governance framework (the "Planned Cooperation Agreement") with Coliseum Capital Management, LLC (together with its managed funds and accounts, "Coliseum"), the largest stockholder of the Company o

    4/13/23 4:05:00 PM ET
    $ADES
    $BIOS
    $LAZY
    Major Chemicals
    Industrials
    Blank Checks
    Finance